In 1994, genetic testing for late-onset Alzheimer's disease became available primarily in research settings, offering patients a probabilistic measure of their risk for the disease by analyzing their apolipoprotein E (ApoE) genotype. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.